Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.58 |
| ▸ | NOD1 | Q9Y239 | 9/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | FAAH | O00519 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | LPAR3 | Q9UBY5 | 2/20 | 0.43 |
| ▸ | SLC6A5 | Q9Y345 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2495617 | 0.90 | KMT2A (0.51) | KMT2ANOD1MEN1FAAHMAPK1 | |
| SCHEMBL27754272 | 0.87 | KMT2A (0.69) | KMT2ANOD1POLBMEN1FAAH | |
| SCHEMBL27754307 | 0.87 | KMT2A (0.69) | KMT2ANOD1POLBMEN1FAAH | |
| SCHEMBL3776147 | 0.87 | KMT2A (0.69) | KMT2ANOD1POLBMEN1FAAH | |
| SCHEMBL3773213 | 0.87 | KMT2A (0.69) | KMT2ANOD1POLBMEN1FAAH | |
| SCHEMBL3773778 | 0.87 | KMT2A (0.69) | KMT2ANOD1POLBMEN1FAAH | |
| SCHEMBL8019564 | 0.87 | KMT2A (0.60) | KMT2ANOD1POLBMEN1FAAH | |
| SCHEMBL28159360 | 0.87 | KMT2A (0.68) | KMT2ANOD1POLBMEN1FAAH | |
| SCHEMBL8019568 | 0.87 | KMT2A (0.60) | KMT2ANOD1POLBMEN1FAAH | |
| SCHEMBL5225925 | 0.87 | KMT2A (0.68) | KMT2ANOD1POLBMEN1FAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230234917-A1 | ASPARAGINE DERIVATIVES AND METHODS OF USING SAME | SENDA BIOSCIENCES INC (US) | 2023-07-27 | — | — | US | disclosed |
| US-20230234917-A1 | ASPARAGINE DERIVATIVES AND METHODS OF USING SAME | SENDA BIOSCIENCES INC (US) | 2023-07-27 | — | — | US | disclosed |
| WO-2021252640-A1 | ASPARAGINE DERIVATIVES AND METHODS OF USING SAME | SENDA BIOSCIENCES, INC. (US) | 2021-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230234917-A1 | ASPARAGINE DERIVATIVES AND METHODS OF USING SAME | ASNS, SI, NARS1 | KMT2A 4069/4885NOD1 751/4885POLB 1641/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.